Literature DB >> 20466021

Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins.

Ripon Paul1, Isaac N Pessah, Louise Gane, Michele Ono, Paul J Hagerman, James A Brunberg, Flora Tassone, James A Bourgeois, Patrick E Adams, Danh V Nguyen, Randi Hagerman.   

Abstract

We present four cases of fragile X premutation carriers with early neurological symptoms, including symptoms consistent with multiple sclerosis (MS) and fragile X-associated tremor/ataxia syndrome (FXTAS). Each patient had significant exposure to one or more environmental neurotoxicants that have documented neurotoxicity (i.e. hexachlorocyclopentadiene or C56, Agent Orange, and 2,4- or 2,6-toluene diisocyanate and dichlormate). We hypothesize that premutation carriers are a vulnerable group to neurotoxins because elevated mRNA in the premutation can lead to early cell death and brain disease, leading to neuropsychiatric and neurological symptoms consistent with FXTAS. (c) 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466021      PMCID: PMC3918243          DOI: 10.1016/j.neuro.2010.04.002

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  29 in total

1.  Fragile X-associated tremor/ataxia syndrome: intrafamilial variability and the size of the FMR1 premutation CGG repeat.

Authors:  Leonardo P Capelli; Márcia R R Gonçalves; Fernando Kok; Cláudia C Leite; Ricardo Nitrini; Egberto R Barbosa; Angela M Vianna-Morgante
Journal:  Mov Disord       Date:  2007-04-30       Impact factor: 10.338

2.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

Review 3.  Neurologic health outcomes and Agent Orange: Institute of Medicine report.

Authors:  C G Goetz; K I Bolla; S M Rogers
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

4.  Intrafamilial variability in fragile X-associated tremor/ataxia syndrome.

Authors:  Nils Peters; Christoph Kamm; Friedrich Asmus; Elke Holinski-Feder; Eduard Kraft; Martin Dichgans; Roland Brüning; Thomas Gasser; Kai Bötzel
Journal:  Mov Disord       Date:  2006-01       Impact factor: 10.338

Review 5.  Environmental fate and bioavailability of Agent Orange and its associated dioxin during the Vietnam War.

Authors:  Alvin L Young; John P Giesy; Paul D Jones; Michael Newton
Journal:  Environ Sci Pollut Res Int       Date:  2004       Impact factor: 4.223

6.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

7.  Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study.

Authors:  Cary S Kogan; Jeremy Turk; Randi J Hagerman; Kim M Cornish
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

8.  Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis.

Authors:  Claudia M Greco; Flora Tassone; Dolores Garcia-Arocena; Nicole Tartaglia; Sarah M Coffey; Timothy K Vartanian; James A Brunberg; Paul J Hagerman; Randi J Hagerman
Journal:  Arch Neurol       Date:  2008-08

9.  Evidence of depressive symptoms in fragile-X syndrome premutated females.

Authors:  Laia Rodriguez-Revenga; Irene Madrigal; Montserrat Alegret; Mónica Santos; Montserrat Milà
Journal:  Psychiatr Genet       Date:  2008-08       Impact factor: 2.458

10.  Effects of inhalation exposure to hexachlorocyclopentadiene on rats and monkeys.

Authors:  G M Rand; P O Nees; C J Calo; D J Alexander; G C Clark
Journal:  J Toxicol Environ Health       Date:  1982 May-Jun
View more
  27 in total

1.  Sleep apnea in fragile X premutation carriers with and without FXTAS.

Authors:  Alyssa Hamlin; Ying Liu; Danh V Nguyen; Flora Tassone; Lin Zhang; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-09-19       Impact factor: 3.568

2.  Mouse models of the fragile x premutation and the fragile X associated tremor/ataxia syndrome.

Authors:  Michael R Hunsaker; Gloria Arque; Robert F Berman; Rob Willemsen; Renate K Hukema
Journal:  Results Probl Cell Differ       Date:  2012

3.  Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder.

Authors:  Weerasak Chonchaiya; Jacky Au; Andrea Schneider; David Hessl; Susan W Harris; Meredith Laird; Yi Mu; Flora Tassone; Danh V Nguyen; Randi J Hagerman
Journal:  Hum Genet       Date:  2011-10-15       Impact factor: 4.132

Review 4.  General Anesthetic Use in Fragile X Spectrum Disorders.

Authors:  Andrew Ligsay; Marwa El-Deeb; Maria J Salcedo-Arellano; Nina Schloemerkemper; Jeremy S Grayson; Randi Hagerman
Journal:  J Neurosurg Anesthesiol       Date:  2019-07       Impact factor: 3.956

Review 5.  Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.

Authors:  Teresa Botta-Orfila; Gian Gaetano Tartaglia; Aubin Michalon
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

6.  Newborn screening and cascade testing for FMR1 mutations.

Authors:  Page L Sorensen; Louise W Gane; Mark Yarborough; Randi J Hagerman; Flora Tassone
Journal:  Am J Med Genet A       Date:  2012-12-13       Impact factor: 2.802

7.  TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.

Authors:  C Kağan Gürkan; Randi J Hagerman
Journal:  Res Autism Spectr Disord       Date:  2012-10-01

8.  Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo.

Authors:  Renate K Hukema; Ronald A M Buijsen; Chris Raske; Lies Anne Severijnen; Ingeborg Nieuwenhuizen-Bakker; Michelle Minneboo; Alex Maas; Rini de Crom; Johan M Kros; Paul J Hagerman; Robert F Berman; Rob Willemsen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

Review 10.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.